- Stocks
- Consumer Cyclical
- NYSE: MED

Price (delayed)

$252.99

Market cap

$2.98B

P/E Ratio

28.95

Dividend/share

$4.52

EPS

$8.74

Enterprise value

$2.83B

The equity has grown by 50% YoY and by 12% from the previous quarter

The EPS has increased by 32% year-on-year and by 8% since the previous quarter

The price to earnings (P/E) is 56% more than the last 4 quarters average of 18.5 and 12% more than the 5-year quarterly average of 25.8

What are the main financial stats of MED

Market
Valuations
Earnings

Shares outstanding

11.77M

Market cap

$2.98B

Enterprise value

$2.83B

Price to earnings (P/E)

28.95

Price to book (P/B)

18.94

Price to sales (P/S)

3.19

EV/EBIT

21.05

EV/EBITDA

19.97

EV/Sales

3.02

Revenue

$934.84M

EBIT

$134.27M

EBITDA

$141.54M

Free cash flow

$139.31M

Per share
Balance sheet
Liquidity

EPS

$8.74

Free cash flow per share

$11.83

Book value per share

$13.36

Revenue per share

$79.42

TBVPS

$23.45

Total assets

$276.08M

Total liabilities

$118.84M

Debt

$11.16M

Equity

$157.25M

Working capital

$122.96M

Debt to equity

0.07

Current ratio

2.1

Quick ratio

1.57

Net debt/EBITDA

-1.08

Margins
Efficiency
Dividend

EBITDA margin

15.1%

Gross margin

74.6%

Net margin

11%

Operating margin

14.4%

Return on assets

42.4%

Return on equity

78.4%

Return on invested capital

817.2%

Return on capital employed

81.5%

Return on sales

14.4%

Dividend yield

1.79%

DPS

$4.52

Payout ratio

56%

How has the Medifast stock price performed over time

Intraday

-0.69%

1 week

-5.68%

1 month

4.1%

1 year

167.77%

YTD

28.85%

QTD

28.85%

How have Medifast's revenue and profit performed over time

Revenue

$934.84M

Gross profit

$697.82M

Operating income

$134.16M

Net income

$102.86M

Gross margin

74.6%

Net margin

11%

The operating income rose by 47% YoY and by 17% QoQ

MED's net income is up by 32% YoY and by 9% QoQ

MED's revenue is up by 31% year-on-year and by 11% since the previous quarter

Medifast's gross profit has increased by 30% YoY and by 11% from the previous quarter

What is Medifast's growth rate over time

What is Medifast stock price valuation

P/E

28.95

P/B

18.94

P/S

3.19

EV/EBIT

21.05

EV/EBITDA

19.97

EV/Sales

3.02

The price to earnings (P/E) is 56% more than the last 4 quarters average of 18.5 and 12% more than the 5-year quarterly average of 25.8

The EPS has increased by 32% year-on-year and by 8% since the previous quarter

MED's P/B is 84% above its 5-year quarterly average of 10.3 and 54% above its last 4 quarters average of 12.3

The equity has grown by 50% YoY and by 12% from the previous quarter

The P/S is 60% higher than the last 4 quarters average of 2.0 and 28% higher than the 5-year quarterly average of 2.5

MED's revenue is up by 31% year-on-year and by 11% since the previous quarter

How efficient is Medifast business performance

The return on invested capital has surged by 87% since the previous quarter

MED's ROE is up by 17% YoY but it is down by 2.2% QoQ

The return on sales has increased by 12% year-on-year and by 5% since the previous quarter

The ROA has increased by 11% YoY

What is MED's dividend history

DPS

$4.52

Dividend yield

1.79%

Payout ratio

56%

Recent dividends

How did Medifast financials performed over time

The total assets is 132% greater than the total liabilities

The total assets is up by 42% year-on-year and by 6% since the previous quarter

The company's quick ratio rose by 32% YoY and by 3.3% QoQ

Medifast's debt is 93% less than its equity

The equity has grown by 50% YoY and by 12% from the previous quarter

Medifast's debt to equity has decreased by 46% YoY and by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.